疏血通注射液联合依达拉奉治疗急性脑梗死的临床疗效及对血清Copeptin、NT-proBNP、Hs-CRP和Hcy水平的影响

Efficacy of ShuXueTong Injection Combined with Edaravone on Patients with Acute Cerebral Infarction and its Effect on Serum Copeptin,NT-proBNP,Hs-CRP and Hcy Levels

目的 研究疏血通注射液联合依达拉奉治疗急性脑梗死患者的临床疗效及对血清Copeptin、NT-proBNP、Hs-CRP和Hcy水平的影响。方法 将70例急性脑梗死患者随机分为对照组(35例)和治疗组(35例),对照组给予依达拉奉注射液治疗,其中,治疗组患者给予疏血通注射液+依达拉奉注射液联合治疗,两组疗程均为2周;采用NIHSS表进行神经功能缺损程度评分,Barthel指数进行生活质量评分,并根据NIHSS评分减少率进行疗效评价,采用ELISA法检测患者治疗前后血清中的Copeptin、NT-proBNP、Hs-CRP和Hcy水平。结果 治疗组患者疗效显著优于对照组患者(P<0.01),治疗后两组患者血清Copeptin、NT-proBNP、Hs-CRP和Hcy水平均显著降低(〖WTBX〗P<0.01),但治疗组患者各项血清指标降低水平显著优于对照组患者(〖WTBX〗P<0.01)。结论 疏血通注射液联合依达拉奉治疗急性脑梗死疗效明显,且可降低患者血清Copeptin、NT-proBNP、Hs-CRP和Hcy水平。

OBJECTIVE To study the efficacy of ShuXueTong injection combined with edaravone on patients with acute cerebral infarction (ACI) and its effect on serum Copeptin,NT-proBNP,Hs-CRP and Hcy levels. METHODS 70 cases of ACI were randomized into two groups,control group (35 cases) and treatment group (35 cases).The patients in control group were administrated with edaravone injection,while the patients in treatment group were administrated with ShuXueTong injection in addition.The treatment protocol lasted for two weeks.Then,the NIHSS score was used to evaluate the neurological deficit,the Bathel index score was used for quality of life.Meanwhile,the serum levels of Copeptin,NT-proBNP,Hs-CRP and Hcy were determined by ELISA assays. RESULTS The patients in treatment group had a better efficacy on ACI therapy,compared with control group ( P <0.01).The serum levels of Copeptin,NT-proBNP,Hs-CRP and Hcy significantly decreased in both groups (P <0.01),while the treatment group had a better reduction (P <0.01). CONCLUSION The combination of ShuXueTong injection and edaravone injection had a fabulous effects on ACI therapy,and can also reduced serum Copeptin,NT-proBNP,Hs-CRP and Hcy levels.